Molecular Modeling and Optimization of Type II E.coli l-Asparginase Activity by in silico Design and in vitro Site-directed Mutagenesis
- PMID: 37634213
- DOI: 10.1007/s10930-023-10149-x
Molecular Modeling and Optimization of Type II E.coli l-Asparginase Activity by in silico Design and in vitro Site-directed Mutagenesis
Abstract
Introduction: L-asparaginase (also known as L-ASNase) is a crucial therapeutic enzyme that is widely used in treatment of ALL (acute lymphoblastic leukemia) as a chemotherapeutic drug. Besides, this enzyme is used in the food industry as a food processing reagent to reduce the content of acrylamide in addition to the clinical industry. The improvement of activity and kinetic parameters of the L-ASNase enzyme may lead to higher efficiency resulting in practical achievement. In order to achieve this goal, we chosen glycine residue in position 88 as a potential mutation with advantageous outcomes.
Method: In this study, firstly to find the appropriate mutation on glycine 88, various in silico analyses, such as MD simulation and molecular docking, were carried out. Then, the rational design was adopted as the best strategy for molecular modifications of the enzyme to improve its enzymatic properties.
Result: Our in silico findings show that the four mutations G88Q, G88L, G88K, and G88A may be able to increase L-ASNase's asparaginase activity. The catalytic efficiency of each enzyme (kcat/Km) is the most important feature for comparing the catalytic activity of the mutants with the wild type form. The laboratory experiments showed that the kcat/Km for the G88Q mutant is 36.32% higher than the Escherichia coli K12 ASNase II (wild type), which suggests that L-ASNase activity is improved at lower concentration of L-ASN. Kinetic characterization of the mutants L-ASNase activity confirmed the high turnover rate (kcat) with ASN as substrate relative to the wild type enzyme.
Conclusion: In silico analyses and laboratory experiments demonstrated that the G88Q mutation rather than other mutation (G88L, G88K, and G88A) could improve the kinetics of L-ASNase.
Keywords: Catalytic activity; Escherichia coli; In silico; Kinetic characterization; L-asparaginase II; Site-directed mutagenesis.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.Med Hypotheses. 2018 Mar;112:7-17. doi: 10.1016/j.mehy.2018.01.004. Epub 2018 Jan 30. Med Hypotheses. 2018. PMID: 29447943
-
Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).Asian Pac J Cancer Prev. 2021 Apr 1;22(4):1137-1147. doi: 10.31557/APJCP.2021.22.4.1137. Asian Pac J Cancer Prev. 2021. PMID: 33906306 Free PMC article.
-
Enhancing the Catalytic Activity of Type II L-Asparaginase from Bacillus licheniformis through Semi-Rational Design.Int J Mol Sci. 2022 Aug 26;23(17):9663. doi: 10.3390/ijms23179663. Int J Mol Sci. 2022. PMID: 36077061 Free PMC article.
-
L-asparaginase production review: bioprocess design and biochemical characteristics.Appl Microbiol Biotechnol. 2021 Jun;105(11):4515-4534. doi: 10.1007/s00253-021-11359-y. Epub 2021 Jun 1. Appl Microbiol Biotechnol. 2021. PMID: 34059941 Review.
-
Microbial production, molecular modification, and practical application of l-Asparaginase: A review.Int J Biol Macromol. 2021 Sep 1;186:975-983. doi: 10.1016/j.ijbiomac.2021.07.107. Epub 2021 Jul 19. Int J Biol Macromol. 2021. PMID: 34293360 Review.
Cited by
-
Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.Int J Mol Sci. 2023 Oct 16;24(20):15220. doi: 10.3390/ijms242015220. Int J Mol Sci. 2023. PMID: 37894901 Free PMC article. Review.
-
Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives - Imidazoline Receptor Agonists.Drug Des Devel Ther. 2024 Apr 3;18:1035-1052. doi: 10.2147/DDDT.S447289. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38585255 Free PMC article.
References
-
- Wang N, Ji W, Wang L, Wu W, Zhang W, Wu Q et al (2022) Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia. RSC Med Chem.
-
- Avramis VI, Tiwari PN (2006) Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomed 1(3):241
LinkOut - more resources
Full Text Sources
Miscellaneous